Local 12: Chemotherapy in recurrent ovarian cancer patients
UC researcher publishes New England Journal of Medicine study looking at outcomes
The five-year survival rate for ovarian cancer is only 36%, one of the worst cancer survival rates out there.
Finding the right treatments, however, is critical to changing that survival rate, according to Dr. Thomas Herzog, a professor at UC and gynecologic oncologist with UC Health. His team just released a study in the New England Journal of Medicine comparing those who just had chemotherapy with a recurrent cancer and those who had chemotherapy in addition to surgery when the cancer came back.
Featured photo courtesy of Unsplash.
Related Stories
Study finds police officers face higher long-term health risks
January 2, 2026
J.C. Barnes, a University of Cincinnati professor, is interviewed by Spectrum News about new research showing that the physical and psychological demands of law enforcement can contribute to earlier deaths.
A partnership to end pancreatic cancer
December 19, 2025
Since 2010, BSI Engineering has raised more than $1.2 million for pancreatic cancer research at the University of Cincinnati Cancer Center in honor of a friend and inspiration to BSI’s founders, Bryan Speicher.
Bazinga! UC physicist cracks ‘Big Bang Theory’ problem
December 19, 2025
A physicist at the University of Cincinnati and his colleagues figured out something two of America’s most famous fictional physicists couldn’t: theoretically how to produce subatomic particles called axions in fusion reactors.